Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma / Yirui Gui, Mehdi Yeganeh, Yuneivy Cepero-Donates, Sheela Ramanathan, Caroline Saucier, Subburaj Ilangumaran
The SOCS1 gene is a frequent target of epigenetic repression in hepatocellular carcinoma. Many other types of cancer also harbor methylated SOCS1 gene. Besides, recent studies implicate microRNAs targeting SOCS1 in cancer progression. These findings suggest a broad tumor suppressor role of SOCS1 and have stimulated the quest to elucidate the underlying molecular mechanisms. The essential physiological function of SOCS1 is to attenuate interferon gamma signaling in immune cells. SOCS1 binds activated JAK kinases and the receptor chains of several cytokines, some of which are implicated in cancer progression. SOCS1 also facilitates ubiquitination and proteasomal degradation of many signaling molecules downstream of cytokine and growth factor receptors. We have shown that SOCS1 inhibits signaling via the hepatocyte growth factor receptor c-MET in hepatocytes. Aberrant MET signaling, implicated in the progression of many types of cancers, also contributes to the development of chemoresistance to tyrosine kinase inhibitors and drugs targeting other oncogenic signaling pathways. Here, we discuss the SOCS1-dependent regulation of MET signaling as an important mechanism underlying the tumor suppressor role of SOCS1 that is relevant not only to hepatocellular carcinoma but also to other types of cancers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 20(2014), 17, Seite 2922- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gui, Yirui [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (12 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL009067582 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL009067582 | ||
| 003 | DE-627 | ||
| 005 | 20231129162111.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220323s2014 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL009067582 | ||
| 035 | |a (KFL)prod_DARH_0011B.sgm.30EAA2E2495380F1FBCD76E3CCE7B753AA5431B7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Gui, Yirui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma |c Yirui Gui, Mehdi Yeganeh, Yuneivy Cepero-Donates, Sheela Ramanathan, Caroline Saucier, Subburaj Ilangumaran |
| 264 | 1 | |c 2014 | |
| 300 | |a 1 Online-Ressource (12 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The SOCS1 gene is a frequent target of epigenetic repression in hepatocellular carcinoma. Many other types of cancer also harbor methylated SOCS1 gene. Besides, recent studies implicate microRNAs targeting SOCS1 in cancer progression. These findings suggest a broad tumor suppressor role of SOCS1 and have stimulated the quest to elucidate the underlying molecular mechanisms. The essential physiological function of SOCS1 is to attenuate interferon gamma signaling in immune cells. SOCS1 binds activated JAK kinases and the receptor chains of several cytokines, some of which are implicated in cancer progression. SOCS1 also facilitates ubiquitination and proteasomal degradation of many signaling molecules downstream of cytokine and growth factor receptors. We have shown that SOCS1 inhibits signaling via the hepatocyte growth factor receptor c-MET in hepatocytes. Aberrant MET signaling, implicated in the progression of many types of cancers, also contributes to the development of chemoresistance to tyrosine kinase inhibitors and drugs targeting other oncogenic signaling pathways. Here, we discuss the SOCS1-dependent regulation of MET signaling as an important mechanism underlying the tumor suppressor role of SOCS1 that is relevant not only to hepatocellular carcinoma but also to other types of cancers | ||
| 700 | 1 | |a Yeganeh, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Cepero-Donates, Yuneivy |e verfasserin |4 aut | |
| 700 | 1 | |a Ramanathan, Sheela |e verfasserin |4 aut | |
| 700 | 1 | |a Saucier, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Ilangumaran, Subburaj |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d Hilversum : Bentham Science Publ., 2000 |g 20(2014), 17, Seite 2922- |h Online-Ressource |w (DE-627)KFL000006327 |w (DE-600)2034245-7 |w (DE-576)273880217 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2014 |g number:17 |g pages:2922- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1381-6128&volume=20&issue=17&spage=2922 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_01 | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2014 |e 17 |h 2922- | ||